Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Lawton CA, et al. Among authors: coughlin ct. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46. doi: 10.1016/s0360-3016(00)01516-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11240234 Clinical Trial.
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Pilepich MV, et al. Among authors: coughlin ct. J Clin Oncol. 1997 Mar;15(3):1013-21. doi: 10.1200/JCO.1997.15.3.1013. J Clin Oncol. 1997. PMID: 9060541 Clinical Trial.
A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases.
Poulter CA, Cosmatos D, Rubin P, Urtasun R, Cooper JS, Kuske RR, Hornback N, Coughlin C, Weigensberg I, Rotman M. Poulter CA, et al. Int J Radiat Oncol Biol Phys. 1992;23(1):207-14. doi: 10.1016/0360-3016(92)90563-w. Int J Radiat Oncol Biol Phys. 1992. PMID: 1374061 Clinical Trial.
Fraction size in external beam radiation therapy in the treatment of melanoma.
Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, JanJan N, Lipsett J. Sause WT, et al. Among authors: coughlin ct. Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):429-32. doi: 10.1016/0360-3016(91)90053-7. Int J Radiat Oncol Biol Phys. 1991. PMID: 1995527 Clinical Trial.
Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P. Coughlin C, et al. Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1351-8. doi: 10.1016/s0360-3016(00)01412-7. Int J Radiat Oncol Biol Phys. 2000. PMID: 11121633 Clinical Trial.
46 results